Kidney care providers merge in $2.4 billion deal

Three kidney care providers –– Fresenius Health Partners, Cricket Health and InterWell Health –– have entered into a binding agreement to merge.

The merger, valued at a whopping $2.4 billion, combines three value-based care companies. Fresenius Health is the value-based care division of Fresenius Medical Care North America. InterWell Health is the leading physician organization driving innovation in the kidney care space in the U.S.  Cricket Health is a U.S. provider of value-based kidney care with a leading patient engagement and data platform.

Each company brings unique synergies to the deal. Fresenius has expertise in kidney care value-based contracting and performance, while InterWell Health boasts clinical care models and a strong network of 1,600 nephrologists. Cricket Health offers its proprietary informatics, StageSmart and patient engagement platforms for its tech-enabled care model.

The merger is part of Fresenius' transformation program FME25, designed to change its operating model to provide the base for future sustainable growth. 

“This effort is an important next step in executing Fresenius Medical Care’s growth strategy 2025 to further expand along the renal care continuum and to refine and grow our future operating model in care delivery in the U.S. as part of the FME25 transformation,” Rice Powell, CEO of Fresenius Medical Care. “In bringing together the expertise and competence of three leading partners we will be broadening our offer and adding significant value to patients with chronic kidney disease all over the U.S.”

The new company will operate under the InterWell Health brand, and Fresenius Health will be the majority owner. The merger will create an independent entity that expands into the $120 billion chronic kidney disease stage 3 to 5 market, according to a press release. The new company will target the care of 270,000 people with kidney disease by 2025 and to manage around $11 billion medical cost in the same year.

The deal is expected to close in the second half of 2022.

Related Kidney Care Content:

AI guides therapeutic decisions for dialysis patients

Algorithm predicts dialysis need in COVID patients upon admission

Dialysis organizations team up with CDC to protect patients

AI charts course of care for chronic kidney disease

Cigna expands partnership with Cricket Health in kidney disease care

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.